Suppr超能文献

联合治疗(经动脉栓塞化疗联合阿霉素和乙醇)对肝细胞癌的疗效。

Efficacy of combination treatment--(TAE with adriamycin and ethanol)--for hepatocellular carcinoma.

作者信息

Hasuike Y, Okamura J, Furukawa J, Naoi M, Takata N, Maruyama H, Kinuta M, Yayoi E, Oi H, Okamoto S

机构信息

Department of Surgery, Osaka Teishin Hospital, Japan.

出版信息

Cancer Chemother Pharmacol. 1992;31 Suppl:S30-4. doi: 10.1007/BF00687101.

Abstract

Among 44 patients with hepatocellular carcinoma (HCC), combination treatment with both transhepatic arterial embolization (TAE) and ethanol injection therapy (EIT) was performed in 10 patients. Only two had tumors measuring less than 3 cm in diameter. In all, eight patients had solitary tumors and two had multiple tumors. The tumor was classified as stage I in one patient, stage II in six subjects, stage III in two patients, and stage IV in one subject prior to TAE, but one stage II case was changed to stage III after laparotomy. The clinical stage was I in two patients, II in six subjects and III in two patients. Five patients with tumors of stages I and II achieved either a complete response (CR) or partial response (PR). However, three patients with tumors of stages III and IV showed progressive disease (PD). Thus, the response rate (CR+PR) was 50%. For tumor stages I and II, the 1-, 2-, and 3-year survival values were 100%, 100%, and 83%, respectively. For tumor stages III and IV, the 1- and 2-year survival values were 75% and 25%, respectively. Combination treatment of HCC appears to be efficacious for tumor stages I and II.

摘要

在44例肝细胞癌(HCC)患者中,10例患者接受了经肝动脉栓塞术(TAE)和乙醇注射疗法(EIT)的联合治疗。只有2例患者的肿瘤直径小于3厘米。总共有8例患者为单发肿瘤,2例为多发肿瘤。在TAE治疗前,1例患者的肿瘤被分类为I期,6例为II期,2例为III期,1例为IV期,但有1例II期病例在剖腹手术后变为III期。临床分期为I期的有2例患者,II期的有6例,III期的有2例。5例I期和II期肿瘤患者实现了完全缓解(CR)或部分缓解(PR)。然而,3例III期和IV期肿瘤患者出现疾病进展(PD)。因此,缓解率(CR + PR)为50%。对于I期和II期肿瘤,1年、2年和3年生存率分别为100%、100%和83%。对于III期和IV期肿瘤,1年和2年生存率分别为75%和25%。HCC的联合治疗似乎对I期和II期肿瘤有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验